Skip to main navigation

Skip to content

About PDL
Leadership
Investor Relations

About PDL
Leadership
Investor Relations

Investor Updates

PDL BioPharma, Inc > Investor Relations > Investor Updates

Investor Updates

Investor Updates

Please see below.

November 10, 2022 – Letter to Investors Regarding Q3 2022 Results 723.5 KB

November 7, 2022 – Order Approving Second Interim Distribution 258.3 KB

August 10, 2022 – Letter to Investors Regarding Q2 2022 Results 380.9 KB

June 2, 2022 – Letter to Investors Regarding Q1 2022 Results 379.2 KB

June 1, 2022 – Financial Statements (Year End 2021) 558 KB

June 1, 2022 – Letter to Investors Regarding Year End 2021 391.9 KB

May 11, 2022 – Letter to Investors Regarding Order Approving Interim Distribution 327 KB

May 10, 2022 – Order Approving Interim Distribution 238.2 KB

February 10, 2022 - Verified Petition For Determination Pursuant To 8 Del. C. Sec. 280(c) 216.2 KB

November 16, 2021 - Letter to Investors Regarding Q3 2021 Results 437.2 KB

Pagination

Current page 1
Page 2
Next page
Last page

Frequently Asked Questions (FAQ)
Investor Updates
Press Releases
Tax Information
- Common Stock Tax Information
- Convertible Note Tax Information
SEC Filings
Contact Information

Printed Materials
Email Alerts
RSS
Print
Share
Search

Facebook
LinkedIn
Twitter
RSS

Terms of Use
Privacy Policy
Sitemap

© Copyright 2023 PDL BioPHARMA. All Rights Reserved.